Skip to main content

Table 3 Cox regression for cancer-specific survival

From: Statin consumption as a risk factor for developing colorectal cancer: a retrospective case study

Cancer-specific survival

Univariate analysis

HR (95% CI)

Multivariate analysis

HR (95% CI)

Statin use

 ‛Former/never’

Ref 1.0

Ref 1.0

 ‛Recent’

1.39 (0.89–2.16)

1.12 (0.64–1.96)

Age

 < 70

Ref 1.0

Ref 1.0

 70–80

1.79 (1.04–3.07)

1.89 (1.09–3.27)

 > 80

2.76 (1.61–4.75

2.67 (1.49–4.76)

Gender

 Male

Ref 1.0

 

 Female

1.11 (0.72–1.72)

 

Diagnosis

 Colon

Ref 1.0

 

 Rectum

0.78 (0.49–1.24)

 

Diabetes

 No

Ref 1.0

 

 Yes

1.56 (0.95–2.55)

 

Previous cancer diagnosis

 No

Ref 1.0

 

 Yes

1.24 (0.66–2.34)

 

Stage

 I + II

0.31 (0.14–0.68)

0.33 (0.15–0.73)

 III

Ref 1.0

Ref 1.0

 IV

7.63 (4.47–13.0)

8.70 (8.70–15.1)

BMI

 < 24.9

Ref 1.0

 

 25–29.9

0.69 (0.42–1.15)

 

 > 30

0.91 (0.52–1.59)

 

NSAID use

 Former and never

Ref 1.0

 

 Recent

0.57 (0.28–1.14)

 

Salicylic acid use

 Former and never

Ref 1.0

Ref 1.0

 Recent

1.67 (1.04–2.68)

1.39 (0.75–2.60)

  1. Cox regression both univariate and multivariate model with cancer-specific survival as endpoint
  2. HR hazard ratio, CI confidence interval, Ref reference, BMI body mass index, NSAID non-steroidal anti-inflammatory drug